Repeated respiratory tract infection is a frequently-occurring disease during childhood. At present, western medicine doctors generally adopt anti-infectives and immunomodulators to treat the disease, while traditiona...Repeated respiratory tract infection is a frequently-occurring disease during childhood. At present, western medicine doctors generally adopt anti-infectives and immunomodulators to treat the disease, while traditional Chinese medicine doctors mainly administer decoction of Chinese herbs. The authors treated 46 cases of repeated respiratory tract infection from March 1990 to April 1996 by applying mild-moxibustion over points on the back with satisfactory therapeutic results. A report follows.Clinical Data All the 86 cases were outpatients in our hospital with duration of common cold for over 10 days and characterized by relapse of respiratory tract infection. There were over 7-time relapse of respiratory tract infection on each case within a year. Eighty-six cases were randomly divided into treatment group (46 cases) and control group (40 cases). Of the 46 cases in the treatment group, 22 were boys and 24 girls. 17 cases (36.9%) were 6 months to 4 years old, 18 (39.1%) 4 to 6 years, and 11 (23.9%) 6 to 12 years. Among the 40 cases in the control group, 19 cases were boys and 21 girls.展开更多
目的四价人乳头瘤病毒疫苗(quadrivalent human papillomavirus,qHPV;HPV6/11/16/18型,临床试验注册号NCT03493542)于2017年在中国境内获批上市,适用于20~45岁女性。这项开放性Ⅲ期临床试验旨在评估并比较9~19岁和20~26岁中国境内女性四...目的四价人乳头瘤病毒疫苗(quadrivalent human papillomavirus,qHPV;HPV6/11/16/18型,临床试验注册号NCT03493542)于2017年在中国境内获批上市,适用于20~45岁女性。这项开放性Ⅲ期临床试验旨在评估并比较9~19岁和20~26岁中国境内女性四价HPV疫苗自第1剂接种至第7个月的免疫原性和安全性。方法9~26岁的受试者分别于第1天、第2个月和第6个月接种3剂次四价HPV疫苗。使用竞争性荧光免疫检测法(cLIA)分析首剂接种当天和第7个月时受试者血清样本中的抗-HPV6/11/16/18抗体几何平均滴度(GMT)和血清抗体阳转率。记录接种后30 d内的注射部位不良事件和全身性不良事件以及整个研究期间出现的严重不良事件。结果本研究共纳入766例接种至少1剂受试者(9~19岁组与20~26岁组各383例)。两个年龄组中所有符合免疫原性方案的受试者在第7个月时,疫苗所含四种HPV型别均产生血清学抗体阳转。9~19岁年龄组受试者在第7个月时产生的抗-HPV6/11/16/18 GMT值非劣效于20~26岁组受试者。9~19岁年龄组中,分别有36.6%和49.3%的受试者报告注射部位不良事件和全身性不良事件,20~26岁年龄组受试者中注射部位和全身性不良事件比例分别为40.7%和54.8%。没有发生疫苗相关严重不良事件。无受试者因不良事件终止研究,无死亡病例的报告。结论9~19岁中国境内女性中接种3剂次四价HPV疫苗后产生的抗体水平非劣效于20~26岁年龄组。该疫苗在研究人群中具有良好的耐受性。展开更多
文摘Repeated respiratory tract infection is a frequently-occurring disease during childhood. At present, western medicine doctors generally adopt anti-infectives and immunomodulators to treat the disease, while traditional Chinese medicine doctors mainly administer decoction of Chinese herbs. The authors treated 46 cases of repeated respiratory tract infection from March 1990 to April 1996 by applying mild-moxibustion over points on the back with satisfactory therapeutic results. A report follows.Clinical Data All the 86 cases were outpatients in our hospital with duration of common cold for over 10 days and characterized by relapse of respiratory tract infection. There were over 7-time relapse of respiratory tract infection on each case within a year. Eighty-six cases were randomly divided into treatment group (46 cases) and control group (40 cases). Of the 46 cases in the treatment group, 22 were boys and 24 girls. 17 cases (36.9%) were 6 months to 4 years old, 18 (39.1%) 4 to 6 years, and 11 (23.9%) 6 to 12 years. Among the 40 cases in the control group, 19 cases were boys and 21 girls.
文摘目的四价人乳头瘤病毒疫苗(quadrivalent human papillomavirus,qHPV;HPV6/11/16/18型,临床试验注册号NCT03493542)于2017年在中国境内获批上市,适用于20~45岁女性。这项开放性Ⅲ期临床试验旨在评估并比较9~19岁和20~26岁中国境内女性四价HPV疫苗自第1剂接种至第7个月的免疫原性和安全性。方法9~26岁的受试者分别于第1天、第2个月和第6个月接种3剂次四价HPV疫苗。使用竞争性荧光免疫检测法(cLIA)分析首剂接种当天和第7个月时受试者血清样本中的抗-HPV6/11/16/18抗体几何平均滴度(GMT)和血清抗体阳转率。记录接种后30 d内的注射部位不良事件和全身性不良事件以及整个研究期间出现的严重不良事件。结果本研究共纳入766例接种至少1剂受试者(9~19岁组与20~26岁组各383例)。两个年龄组中所有符合免疫原性方案的受试者在第7个月时,疫苗所含四种HPV型别均产生血清学抗体阳转。9~19岁年龄组受试者在第7个月时产生的抗-HPV6/11/16/18 GMT值非劣效于20~26岁组受试者。9~19岁年龄组中,分别有36.6%和49.3%的受试者报告注射部位不良事件和全身性不良事件,20~26岁年龄组受试者中注射部位和全身性不良事件比例分别为40.7%和54.8%。没有发生疫苗相关严重不良事件。无受试者因不良事件终止研究,无死亡病例的报告。结论9~19岁中国境内女性中接种3剂次四价HPV疫苗后产生的抗体水平非劣效于20~26岁年龄组。该疫苗在研究人群中具有良好的耐受性。
